Discounted Cash Flow
Ironwood Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $274.0m | $-81.7m | $-29.6m | -29.8% | — |
| 2017 | $298.3m (8.9%) | $-116.9m (-43.1%) | $-103.8m (-250.1%) | -39.2% (-31.4%) | — |
| 2018 | $346.6m (16.2%) | $-282.4m (-141.5%) | $-79.5m (23.4%) | -81.5% (-107.8%) | — |
| 2019 | $428.4m (23.6%) | $21.5m (107.6%) | $3.5m (104.4%) | 5.0% (106.2%) | $0.14 |
| 2020 | $389.5m (-9.1%) | $106.2m (393.7%) | $167.0m (4622.7%) | 27.3% (443.0%) | $0.67 (378.6%) |
| 2021 | $413.8m (6.2%) | $528.4m (397.7%) | $261.6m (56.7%) | 127.7% (368.6%) | $3.26 (386.6%) |
| 2022 | $410.6m (-0.8%) | $175.1m (-66.9%) | $273.6m (4.6%) | 42.6% (-66.6%) | $1.13 (-65.3%) |
| 2023 | $442.7m (7.8%) | $-1.0b (-672.5%) | $183.2m (-33.1%) | -226.4% (-630.9%) | $-6.45 (-670.8%) |
| 2024 | $351.4m (-20.6%) | $880.0k (100.1%) | $103.4m (-43.5%) | 0.3% (100.1%) | $0.01 (100.2%) |
| 2025 | $296.2m (-15.7%) | $24.0m (2629.2%) | $127.0m (22.8%) | 8.1% (3138.4%) | $0.15 (1400.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.